Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 28;2(1):136.
doi: 10.1186/2193-1801-2-136. Print 2013 Dec.

Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes

Hee Kyung Ahn #  1 , Yeon Hee Park #  1 , Su Jin Lee  1 , Silvia Park  1 , Chi Hoon Maeng  1 , Won Park  2 , Doo Ho Choi  2 , Seung Jae Hur  2 , Jin Seok Ahn  1 , Young-Hyuck Im  1
Affiliations

Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes

Hee Kyung Ahn et al. Springerplus. .

Abstract

The aims of the present study were to investigate how breast cancer (BC) subtypes and treatment affect time to brain metastasis (TTBM). We retrospectively investigated 189 consecutive patients who were diagnosed with brain metastasis (BM) from BC between 2000 and 2009 at Samsung Medical Center. We analyzed TTBM from initial diagnosis of metastatic BC according to subtypes and trastzumab (T) administration before BM diagnosis. The median age of 189 BM patients from BC was 48 years. We divided TTBM into four groups considering BC subtypes and treatment; HR-positive/HER2-negative (n=45), HER2-positive with T before BM development (n=47), HER2-positive without T before BM development (n=39), and TNBC (n=58). The median TTBMs for each group were 17.5 months, 13.7 months, 5.8 months, and 2.9 months, respectively (p<0.001). HER2-positive without T (HR 1.892, p=0.008) and TNBC (HR 1.652, p=0.023) were independently associated with shorter TTBM. In multivariate analysis, HER2-positive without T (hazard ratio 1.725, p=0.002) and TNBC (hazard ratio 1.579, p=0.022) were independent risk factors for worse metastatic OS compared with HR-positive/HER2-negative subtype. TTBMs were shorter in patients with HER2-positive without T and TNBC among BC subtypes. Prospective clinical study for high risk patients for early BM is warranted.

Keywords: Brain metastases; Breast cancer; HER2; Trastuzumab; Triple negative.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients’ cohort.
Figure 2
Figure 2
Time to brain metastases (TTBM) according to breast cancer subtype. (A)Time to brain metastases from diagnosis of primary breast cancer according to subtype and trastuzumab administration before brain metastases development. (B)Time to brain metastases from initial diagnosis of metastatic breast cancer according to subtype and trastuzumab administration before brain metastases development.
Figure 3
Figure 3
Overall survival from the initial diagnosis of distant metastases according to breast cancer subtype.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH. Neuro Oncol. 2012. Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. - PMC - PubMed
    1. Al-Shamy G, Sawaya R. Management of brain metastases: the indispensable role of surgery. J Neurooncol. 2009;92(3):275–282. doi: 10.1007/s11060-009-9839-y. - DOI - PubMed
    1. Chargari C, Campana F, Pierga JY, Vedrine L, Ricard D, Le Moulec S, Fourquet A, Kirova YM. Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat Rev Clin Oncol. 2010;7(11):632–640. doi: 10.1038/nrclinonc.2010.119. - DOI - PubMed
    1. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska-Mielcarek K, Karpinska A, Staroslawska E, Kubiatowski T, Szczylik C. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat. 2009;117(2):297–303. doi: 10.1007/s10549-008-0275-z. - DOI - PubMed
    1. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010;28(12):2032–2037. doi: 10.1200/JCO.2009.24.6314. - DOI - PubMed

LinkOut - more resources